Expanded Access Policy

NextCure is committed to developing promising new immunomedicines to address the unmet medical needs of patients suffering from rare and seriously debilitating cancer and other immune-related diseases.

We currently have early-stage investigational medicines in our product pipeline for the treatment of cancer. Our goal is to provide access to our medicines at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe that enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal.

We do recognize that some patients will not be eligible for our clinical trials and may wish to access our products through expanded access. However, at this time, we do not offer expanded access to the use of our investigational medicines independent of our clinical trials.

We encourage all patients and physicians who are interested in accessing our investigational medicines to contact us at “[email protected]” to find out more about enrollment.

NextCure may revise this expanded access policy at any time.

If you have any questions, please reach out to us at “[email protected]”. You can find further contact details on the contact page of our website.